BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11:35. [PMID: 29499750 DOI: 10.1186/s13045-018-0571-y] [Cited by in Crossref: 174] [Cited by in F6Publishing: 155] [Article Influence: 58.0] [Reference Citation Analysis]
Number Citing Articles
1 Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. Am Soc Clin Oncol Educ Book 2019;39:433-44. [PMID: 31099694 DOI: 10.1200/EDBK_238691] [Cited by in Crossref: 75] [Cited by in F6Publishing: 34] [Article Influence: 37.5] [Reference Citation Analysis]
2 Hiramatsu H, Adachi S, Umeda K, Kato I, Eldjerou L, Agostinho AC, Natsume K, Tokushige K, Watanabe Y, Grupp SA. Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia. Int J Hematol 2020;111:303-10. [PMID: 31709501 DOI: 10.1007/s12185-019-02771-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Thakar MS, Kearl TJ, Malarkannan S. Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy. Front Oncol 2019;9:1529. [PMID: 32076597 DOI: 10.3389/fonc.2019.01529] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
4 Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM, Roda-Santacruz A, González-Cortijo L, Sotres-Fernández G, Martí-Ballesteros EM, Luque-Pinilla JM, Almagro-Casado E, La Coma-Lanuza FJ, Barrena-Puertas R, Malo-Benages EJ, Monforte-Gómez MJ, Diez-Munar R, Merino-Lanza E, Comeche-Casanova L, Remirez-de-Esparza-Otero M, Correyero-Plaza M, Recio-Rodríguez M, Rodríguez-López M, Sánchez-Manzano MD, Andreu-Vázquez C, Thuissard-Vasallo IJ, María-Tomé JME, Carnevali-Ruiz D. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). EClinicalMedicine 2020;28:100591. [PMID: 33078138 DOI: 10.1016/j.eclinm.2020.100591] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 32.0] [Reference Citation Analysis]
5 Huang C, Zhang HC, Ho JY, Liu RX, Wang L, Kuang N, Zheng MR, Liu LH, Li JQ. Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report. Oncol Lett 2020;20:21. [PMID: 32774494 DOI: 10.3892/ol.2020.11882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zavras PD, Wang Y, Gandhi A, Lontos K, Delgoffe GM. Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date. Onco Targets Ther 2019;12:4543-54. [PMID: 31354288 DOI: 10.2147/OTT.S177844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Myers GD, Verneris MR, Goy A, Maziarz RT. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. J Immunother Cancer 2021;9:e002056. [PMID: 33846220 DOI: 10.1136/jitc-2020-002056] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Dinner S, Liedtke M. Antibody-based therapies in patients with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2018;2018:9-15. [PMID: 30504286 DOI: 10.1182/asheducation-2018.1.9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
9 Gill S, Brudno JN. CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions. Am Soc Clin Oncol Educ Book 2021;41:1-20. [PMID: 33989023 DOI: 10.1200/EDBK_320085] [Reference Citation Analysis]
10 Gluck WL, Callahan SP, Brevetta RA, Stenbit AE, Smith WM, Martin JC, Blenda AV, Arce S, Edenfield WJ. Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19. Respir Med 2020;175:106188. [PMID: 33190086 DOI: 10.1016/j.rmed.2020.106188] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
11 Lin Q, Zhao J, Song Y, Liu D. Recent updates on CAR T clinical trials for multiple myeloma. Mol Cancer 2019;18:154. [PMID: 31684964 DOI: 10.1186/s12943-019-1092-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 21.5] [Reference Citation Analysis]
12 Jiang Z, Liao R, Lv J, Li S, Zheng D, Qin L, Wu D, Chen S, Long Y, Wu Q, Wang S, Lin S, Huang X, Tang Z, Shi P, Zhou H, Liu Q, Zhao R, Li Y, Jie Y, Wei W, Lai P, Du X, Cui S, Weinkove R, Liu P, Pei D, Yao Y, Li P. IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia 2021;35:1380-91. [PMID: 33168950 DOI: 10.1038/s41375-020-01085-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Jin Y, Dong Y, Zhang J, Sun J, Liu Y, Chen Y. The toxicity of cell therapy: Mechanism, manifestations, and challenges. J Appl Toxicol 2021;41:659-67. [DOI: 10.1002/jat.4100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Abbasi A, Peeke S, Shah N, Mustafa J, Khatun F, Lombardo A, Abreu M, Elkind R, Fehn K, de Castro A, Wang Y, Derman O, Nelson R, Uehlinger J, Gritsman K, Sica RA, Kornblum N, Mantzaris I, Shastri A, Janakiram M, Goldfinger M, Verma A, Braunschweig I, Bachier-Rodriguez L. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. J Hematol Oncol 2020;13:1. [PMID: 31900191 DOI: 10.1186/s13045-019-0838-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 32.0] [Reference Citation Analysis]
15 Ciner AT, Hochster HS, August DA, Carpizo DR, Spencer KR. Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review. Immunotherapy 2021;13:1071-8. [PMID: 34287029 DOI: 10.2217/imt-2020-0329] [Reference Citation Analysis]
16 Liu Q, Xu Y, Mou J, Tang K, Fu X, Li Y, Xing Y, Rao Q, Xing H, Tian Z, Wang M, Wang J. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model. Cytotherapy 2020;22:552-62. [PMID: 32747298 DOI: 10.1016/j.jcyt.2020.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
17 Pabst T, Joncourt R, Shumilov E, Heini A, Wiedemann G, Legros M, Seipel K, Schild C, Jalowiec K, Mansouri Taleghani B, Fux M, Novak U, Porret N, Zeerleder S, Bacher U. Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome. Exp Hematol 2020;88:7-14.e3. [PMID: 32673688 DOI: 10.1016/j.exphem.2020.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kang L, Tang X, Zhang J, Li M, Xu N, Qi W, Tan J, Lou X, Yu Z, Sun J, Wang Z, Dai H, Chen J, Lin G, Wu D, Yu L. Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes. Exp Hematol Oncol 2020;9:11. [PMID: 32523801 DOI: 10.1186/s40164-020-00166-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
19 Adkins S. CAR T-Cell Therapy: Adverse Events and Management. J Adv Pract Oncol 2019;10:21-8. [PMID: 33520343 DOI: 10.6004/jadpro.2019.10.4.11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
20 Alexander M, Culos K, Roddy J, Shaw JR, Bachmeier C, Shigle TL, Mahmoudjafari Z. Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. Transplant Cell Ther 2021;27:558-70. [PMID: 33910041 DOI: 10.1016/j.jtct.2021.01.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Macpherson AM, Barry SC, Ricciardelli C, Oehler MK. Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. JCM 2020;9:2967. [DOI: 10.3390/jcm9092967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
22 Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol 2020;38:415-22. [PMID: 31815579 DOI: 10.1200/JCO.19.01892] [Cited by in Crossref: 48] [Cited by in F6Publishing: 25] [Article Influence: 24.0] [Reference Citation Analysis]
23 Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunology 2019;8:e1049. [PMID: 31110702 DOI: 10.1002/cti2.1049] [Cited by in Crossref: 91] [Cited by in F6Publishing: 70] [Article Influence: 45.5] [Reference Citation Analysis]
24 Levin A, Shah NN. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas. Am J Hematol 2019;94:S18-23. [PMID: 30652353 DOI: 10.1002/ajh.25403] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
25 Dholaria BR, Bachmeier CA, Locke F. Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities. BioDrugs. 2019;33:45-60. [PMID: 30560413 DOI: 10.1007/s40259-018-0324-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
26 Liu D, Zhao J, Song Y, Luo X, Yang T. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. J Hematol Oncol 2019;12:15. [PMID: 30736842 DOI: 10.1186/s13045-019-0703-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
27 Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. JAMA Netw Open 2020;3:e202072. [PMID: 32250433 DOI: 10.1001/jamanetworkopen.2020.2072] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 19.0] [Reference Citation Analysis]
28 Gofshteyn JS, Shaw PA, Teachey DT, Grupp SA, Maude S, Banwell B, Chen F, Lacey SF, Melenhorst JJ, Edmonson MJ, Panzer J, Barrett DM, McGuire JL. Neurotoxicity after CTL019 in a pediatric and young adult cohort. Ann Neurol 2018;84:537-46. [PMID: 30178481 DOI: 10.1002/ana.25315] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 14.3] [Reference Citation Analysis]
29 Azoulay E, Shimabukuro-Vornhagen A, Darmon M, von Bergwelt-Baildon M. Critical Care Management of Chimeric Antigen Receptor T Cell-related Toxicity. Be Aware and Prepared. Am J Respir Crit Care Med 2019;200:20-3. [PMID: 30676776 DOI: 10.1164/rccm.201810-1945ED] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 18.0] [Reference Citation Analysis]
30 Freeman TL, Swartz TH. Targeting the NLRP3 Inflammasome in Severe COVID-19. Front Immunol 2020;11:1518. [PMID: 32655582 DOI: 10.3389/fimmu.2020.01518] [Cited by in Crossref: 99] [Cited by in F6Publishing: 81] [Article Influence: 99.0] [Reference Citation Analysis]
31 Zhang X, Yang J, Li J, Li W, Song D, Lu XA, Wu F, Li J, Chen D, Li X, Xu Z, Liu S, Li Z, Ying K, Lu P. Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia. Cancer Immunol Immunother 2021. [PMID: 34365516 DOI: 10.1007/s00262-021-03009-z] [Reference Citation Analysis]
32 Ma F, Ho JY, Du H, Xuan F, Wu X, Wang Q, Wang L, Liu Y, Ba M, Wang Y, Luo J, Li J. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia. Hematol Oncol 2019;37:601-8. [PMID: 31465532 DOI: 10.1002/hon.2672] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
33 Reagan PM, Neelapu SS. How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies. JCO 2021;39:456-66. [DOI: 10.1200/jco.20.01616] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
34 Wright CM, LaRiviere MJ, Baron JA, Uche C, Xiao Y, Arscott WT, Anstadt EJ, Barsky AR, Miller D, LaRose MI, Landsburg DJ, Svoboda J, Nasta SD, Gerson JN, Barta SK, Chong EA, Schuster SJ, Paydar I, Maity A, Plastaras JP. Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma. Int J Radiat Oncol Biol Phys 2020;108:178-88. [PMID: 32446950 DOI: 10.1016/j.ijrobp.2020.05.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
35 Gao CE, Song Q, Zhang M, Li J, Miao Y, Li Z, Dong J. Generation, ex vivo expansion and safety of engineered PD1-knockout primary T cells from cynomolgus macaques. Mol Immunol 2020;124:100-8. [PMID: 32554100 DOI: 10.1016/j.molimm.2020.05.007] [Reference Citation Analysis]
36 Jain T, Litzow MR. No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Blood Adv 2018;2:3393-403. [PMID: 30482769 DOI: 10.1182/bloodadvances.2018020198] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
37 Perez-Amill L, Marzal B, Urbano-Ispizua A, Juan M, Martín-Antonio B. CAR-T Cell Therapy: A Door Is Open to Find Innumerable Possibilities of Treatments for Cancer Patients. Turk J Haematol 2018;35:217-28. [PMID: 30185400 DOI: 10.4274/tjh.2018.0196] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 Liu D. CAR-T "the living drugs", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. J Hematol Oncol 2019;12:113. [PMID: 31703740 DOI: 10.1186/s13045-019-0819-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 13.5] [Reference Citation Analysis]
39 Sukari A, Abdallah N, Nagasaka M. Unleash the power of the mighty T cells-basis of adoptive cellular therapy. Crit Rev Oncol Hematol 2019;136:1-12. [PMID: 30878123 DOI: 10.1016/j.critrevonc.2019.01.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
40 Liu S, Deng B, Yin Z, Lin Y, An L, Liu D, Pan J, Yu X, Chen B, Wu T, Chang AH, Tong C. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol 2021;96:671-9. [PMID: 33725422 DOI: 10.1002/ajh.26160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Liu S, Yin Z, Yu X, Zhao Y, Pan J, Song Y. CD19-specific CAR-T cell therapy for relapsed/refractory non-B-cell acute leukaemia with CD19 antigen expression. Eur J Cancer 2021;153:1-4. [PMID: 34126332 DOI: 10.1016/j.ejca.2021.04.042] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Burns EA, Gentille C, Trachtenberg B, Pingali SR, Anand K. Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. Diseases 2021;9:20. [PMID: 33802788 DOI: 10.3390/diseases9010020] [Reference Citation Analysis]
43 Chou CK, Turtle CJ. Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy. Bone Marrow Transplant 2019;54:780-4. [PMID: 31431714 DOI: 10.1038/s41409-019-0602-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 21.0] [Reference Citation Analysis]
44 Pytlik R, Polgarova K, Karolova J, Klener P. Current Immunotherapy Approaches in Non-Hodgkin Lymphomas. Vaccines (Basel) 2020;8:E708. [PMID: 33260966 DOI: 10.3390/vaccines8040708] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Zhang LN, Song Y, Liu D. CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies. J Hematol Oncol 2018;11:41. [PMID: 29544528 DOI: 10.1186/s13045-018-0593-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
46 Jin A, Feng J, Wang Z, Jiang L, Hu Y, Zhao K, Huang H. Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy. Bone Marrow Transplant 2019;54:969-72. [PMID: 30563981 DOI: 10.1038/s41409-018-0412-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
47 Garcia Borrega J, Gödel P, Rüger MA, Onur ÖA, Shimabukuro-Vornhagen A, Kochanek M, Böll B. In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy. Hemasphere 2019;3:e191. [PMID: 31723828 DOI: 10.1097/HS9.0000000000000191] [Cited by in Crossref: 48] [Cited by in F6Publishing: 14] [Article Influence: 24.0] [Reference Citation Analysis]
48 Makita S, Imaizumi K, Kurosawa S, Tobinai K. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. Drugs Context 2019;8:212567. [PMID: 30815024 DOI: 10.7573/dic.212567] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
49 Dzobo K, Chiririwa H, Dandara C, Dzobo W. Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine. OMICS 2021;25:13-22. [PMID: 32857671 DOI: 10.1089/omi.2020.0122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag 2019;15:323-35. [PMID: 30880998 DOI: 10.2147/TCRM.S150524] [Cited by in Crossref: 47] [Cited by in F6Publishing: 25] [Article Influence: 23.5] [Reference Citation Analysis]
51 Grywalska E, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, Niedźwiedzka-Rystwej P, Roliński J. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy. Cells 2020;9:E983. [PMID: 32316105 DOI: 10.3390/cells9040983] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
52 Bonaldo G, Montanaro N, AlbertoVaccheri, Motola D. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice. Eur J Clin Pharmacol 2021;77:1225-34. [PMID: 33608749 DOI: 10.1007/s00228-021-03106-z] [Reference Citation Analysis]
53 Oved JH, Barrett DM, Teachey DT. Cellular therapy: Immune-related complications. Immunol Rev 2019;290:114-26. [PMID: 31355491 DOI: 10.1111/imr.12768] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 25.0] [Reference Citation Analysis]
54 Du M, Hari P, Hu Y, Mei H. Biomarkers in individualized management of chimeric antigen receptor T cell therapy. Biomark Res 2020;8:13. [PMID: 32426136 DOI: 10.1186/s40364-020-00190-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
55 Liu D, Zhao J. Cytokine release syndrome: grading, modeling, and new therapy. J Hematol Oncol 2018;11:121. [PMID: 30249264 DOI: 10.1186/s13045-018-0653-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 19.3] [Reference Citation Analysis]
56 Li NN, Liu LH, Yang JF, Fan LJ, Gao XX, Yin DX, Lu PH, Zhang JP. [allo-CD19-CAR-T cells therapy followed with same-donor allo-HSCT to treat relapsed B-ALL: two cases report and literatures review]. Zhonghua Xue Ye Xue Za Zhi 2020;41:943-5. [PMID: 33333700 DOI: 10.3760/cma.j.issn.0253-2727.2020.11.012] [Reference Citation Analysis]
57 Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol 2019;10:2040620719841581. [PMID: 31019670 DOI: 10.1177/2040620719841581] [Cited by in Crossref: 80] [Cited by in F6Publishing: 65] [Article Influence: 40.0] [Reference Citation Analysis]
58 Belin C, Devic P, Ayrignac X, Dos Santos A, Paix A, Sirven-Villaros L, Simard C, Lamure S, Gastinne T, Ursu R, Berger C, Platon L, Tessoulin B, Azoulay E, Wallet F, Thieblemont C, Bachy E, Cartron G, Laplaud DA, Carpentier AF. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Sci Rep 2020;10:18997. [PMID: 33149178 DOI: 10.1038/s41598-020-76055-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
59 Herrera L, Santos S, Vesga MA, Anguita J, Martin-Ruiz I, Carrascosa T, Juan M, Eguizabal C. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Sci Rep 2019;9:18729. [PMID: 31822751 DOI: 10.1038/s41598-019-55239-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 14.0] [Reference Citation Analysis]
60 Huang H, Wu HW, Hu YX. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. J Zhejiang Univ Sci B 2020;21:29-41. [PMID: 31898440 DOI: 10.1631/jzus.B1900351] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
61 Liu S, Deng B, Yin Z, Pan J, Lin Y, Ling Z, Wu T, Chen D, Chang AH, Gao Z, Song Y, Zhao Y, Tong C. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J 2020;10:15. [PMID: 32029707 DOI: 10.1038/s41408-020-0280-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 24.0] [Reference Citation Analysis]
62 Cao JX, Wang H, Gao WJ, You J, Wu LH, Wang ZX. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy 2020;22:214-26. [PMID: 32305113 DOI: 10.1016/j.jcyt.2020.01.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
63 Pennisi M, Jain T, Santomasso BD, Mead E, Wudhikarn K, Silverberg ML, Batlevi Y, Shouval R, Devlin SM, Batlevi C, Brentjens RJ, Dahi PB, Diamonte C, Giralt S, Halton EF, Maloy M, Palomba ML, Sanchez-Escamilla M, Sauter CS, Scordo M, Shah G, Park JH, Perales MA. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv 2020;4:676-86. [PMID: 32084260 DOI: 10.1182/bloodadvances.2019000952] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 41.0] [Reference Citation Analysis]
64 Sauter CS, Senechal B, Rivière I, Ni A, Bernal Y, Wang X, Purdon T, Hall M, Singh AN, Szenes VZ, Yoo S, Dogan A, Wang Y, Moskowitz CH, Giralt S, Matasar MJ, Perales MA, Curran KJ, Park J, Sadelain M, Brentjens RJ. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood 2019;134:626-35. [PMID: 31262783 DOI: 10.1182/blood.2018883421] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
65 Poorebrahim M, Sadeghi S, Fakhr E, Abazari MF, Poortahmasebi V, Kheirollahi A, Askari H, Rajabzadeh A, Rastegarpanah M, Linē A, Cid-Arregui A. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects. Crit Rev Clin Lab Sci 2019;56:393-419. [PMID: 31314617 DOI: 10.1080/10408363.2019.1633512] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
66 Rahal I, Cabannes-hamy A, Boissel N. Traitement par CAR-T des leucémies aiguës de l'adulte. Bulletin du Cancer 2018;105:S158-67. [DOI: 10.1016/s0007-4551(19)30046-3] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
67 Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant 2021;56:552-66. [PMID: 33230186 DOI: 10.1038/s41409-020-01134-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
68 Hao Z, Li R, Meng L, Han Z, Hong Z. Macrophage, the potential key mediator in CAR-T related CRS. Exp Hematol Oncol 2020;9:15. [PMID: 32665874 DOI: 10.1186/s40164-020-00171-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
69 Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Müller-Tidow C, Dreger P. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol 2021;32:34-48. [PMID: 33098993 DOI: 10.1016/j.annonc.2020.10.478] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
70 Marquez CP, Montiel-Esparza R, Hui C, Schultz LM, Davis KL, Hoppe RT, Donaldson SS, Ramakrishna S, Hiniker SM. Use of cardiac radiation therapy as bridging therapy to CAR-T for relapsed pediatric B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2021;68:e28870. [PMID: 33355997 DOI: 10.1002/pbc.28870] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Kersten MJ, Spanjaart AM, Thieblemont C. CD19-directed CAR T-cell therapy in B-cell NHL. Curr Opin Oncol 2020;32:408-17. [PMID: 32740094 DOI: 10.1097/CCO.0000000000000668] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
72 Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 2019;16:372-85. [PMID: 30837712 DOI: 10.1038/s41571-019-0184-6] [Cited by in Crossref: 131] [Cited by in F6Publishing: 156] [Article Influence: 65.5] [Reference Citation Analysis]
73 Zhang X, Lu XA, Yang J, Zhang G, Li J, Song L, Su Y, Shi Y, Zhang M, He J, Song D, Lv F, Li W, Wu Y, Wang H, Liu H, Zhou X, He T, Lu P. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv 2020;4:2325-38. [PMID: 32453841 DOI: 10.1182/bloodadvances.2020001466] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 23.0] [Reference Citation Analysis]
74 Hay KA. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Br J Haematol 2018;183:364-74. [PMID: 30407609 DOI: 10.1111/bjh.15644] [Cited by in Crossref: 64] [Cited by in F6Publishing: 44] [Article Influence: 21.3] [Reference Citation Analysis]
75 Stein-Merlob AF, Rothberg MV, Holman P, Yang EH. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. Curr Cardiol Rep 2021;23:11. [PMID: 33483873 DOI: 10.1007/s11886-021-01440-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
76 Herrera L, Juan M, Eguizabal C. Purification, Culture, and CD19-CAR Lentiviral Transduction of Adult and Umbilical Cord Blood NK Cells. Curr Protoc Immunol 2020;131:e108. [PMID: 33017099 DOI: 10.1002/cpim.108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
77 Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol 2020;146:940-8. [PMID: 32771558 DOI: 10.1016/j.jaci.2020.07.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
78 Boyiadzis MM, Aksentijevich I, Arber DA, Barrett J, Brentjens RJ, Brufsky J, Cortes J, De Lima M, Forman SJ, Fuchs EJ, Fukas LJ, Gore SD, Litzow MR, Miller JS, Pagel JM, Waller EK, Tallman MS. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. J Immunother Cancer 2020;8:e000810. [PMID: 33077513 DOI: 10.1136/jitc-2020-000810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Liu D, Zhao J, Song Y. Engineering switchable and programmable universal CARs for CAR T therapy. J Hematol Oncol 2019;12:69. [PMID: 31272471 DOI: 10.1186/s13045-019-0763-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 15.0] [Reference Citation Analysis]
80 Cahill KE, Leukam MJ, Riedell PA. Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma. Leukemia & Lymphoma 2020;61:799-807. [DOI: 10.1080/10428194.2019.1691201] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
81 Davey AS, Call ME, Call MJ. The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities. Cancers (Basel) 2020;13:E38. [PMID: 33375550 DOI: 10.3390/cancers13010038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
82 Halford Z, Anderson MK, Bennett LL. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma. Ann Pharmacother 2021;55:390-405. [PMID: 32698673 DOI: 10.1177/1060028020944233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
83 Schuster SJ, Maziarz RT, Rusch ES, Li J, Signorovitch JE, Romanov VV, Locke FL, Maloney DG. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv 2020;4:1432-9. [PMID: 32271899 DOI: 10.1182/bloodadvances.2019001304] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 21.0] [Reference Citation Analysis]
84 Gust J, Taraseviciute A, Turtle CJ. Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. CNS Drugs. 2018;32:1091-1101. [PMID: 30387077 DOI: 10.1007/s40263-018-0582-9] [Cited by in Crossref: 81] [Cited by in F6Publishing: 61] [Article Influence: 40.5] [Reference Citation Analysis]
85 Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest 2020;130:1586-94. [PMID: 32235098 DOI: 10.1172/JCI129208] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 25.0] [Reference Citation Analysis]
86 Gutierrez C, Brown ART, Herr MM, Kadri SS, Hill B, Rajendram P, Duggal A, Turtle CJ, Patel K, Lin Y, May HP, Gallo de Moraes A, Maus MV, Frigault MJ, Brudno JN, Athale J, Shah NN, Kochenderfer JN, Dharshan A, Beitinjaneh A, Arias AS, McEvoy C, Mead E, Stephens RS, Nates JL, Neelapu SS, Pastores SM. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. J Crit Care 2020;58:58-64. [PMID: 32361219 DOI: 10.1016/j.jcrc.2020.04.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
87 Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839-852. [PMID: 32888407 DOI: 10.1016/s0140-6736(20)31366-0] [Cited by in Crossref: 129] [Cited by in F6Publishing: 65] [Article Influence: 129.0] [Reference Citation Analysis]
88 Dushenkov A, Jungsuwadee P. Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice. J Oncol Pharm Pract 2019;25:1217-25. [PMID: 30890066 DOI: 10.1177/1078155219836480] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
89 Mahmoudjafari Z, Hawks KG, Hsieh AA, Plesca D, Gatwood KS, Culos KA. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States. Biol Blood Marrow Transplant 2019;25:26-33. [PMID: 30266675 DOI: 10.1016/j.bbmt.2018.09.024] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 11.7] [Reference Citation Analysis]
90 Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol 2018;11:81. [PMID: 29895316 DOI: 10.1186/s13045-018-0627-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
91 Wall DA, Krueger J. Chimeric antigen receptor T cell therapy comes to clinical practice. Curr Oncol 2020;27:S115-23. [PMID: 32368181 DOI: 10.3747/co.27.5283] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 16.0] [Reference Citation Analysis]
92 Yu S, Yi M, Qin S, Wu K. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019;18:125. [PMID: 31429760 DOI: 10.1186/s12943-019-1057-4] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 37.0] [Reference Citation Analysis]
93 Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol 2019;37 Suppl 1:48-52. [PMID: 31187535 DOI: 10.1002/hon.2595] [Cited by in Crossref: 75] [Cited by in F6Publishing: 61] [Article Influence: 37.5] [Reference Citation Analysis]
94 Roth P, Winklhofer S, Müller AMS, Dummer R, Mair MJ, Gramatzki D, Le Rhun E, Manz MG, Weller M, Preusser M. Neurological complications of cancer immunotherapy. Cancer Treat Rev 2021;97:102189. [PMID: 33872978 DOI: 10.1016/j.ctrv.2021.102189] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Crotty E, Downey K, Ferrerosa L, Flores C, Hegde B, Raskin S, Hwang E, Vitanza N, Okada H. Considerations when treating high-grade pediatric glioma patients with immunotherapy. Expert Rev Neurother 2021;21:205-19. [PMID: 33225764 DOI: 10.1080/14737175.2020.1855144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
96 Levine JE, Grupp SA, Pulsipher MA, Dietz AC, Rives S, Myers GD, August KJ, Verneris MR, Buechner J, Laetsch TW, Bittencourt H, Baruchel A, Boyer MW, De Moerloose B, Qayed M, Davies SM, Phillips CL, Driscoll TA, Bader P, Schlis K, Wood PA, Mody R, Yi L, Leung M, Eldjerou LK, June CH, Maude SL. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. J Immunother Cancer 2021;9:e002287. [PMID: 34353848 DOI: 10.1136/jitc-2020-002287] [Reference Citation Analysis]
97 Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, Shyu A, Highfill SL, Price A, Zhao L, Peng L, Granda B, Ramones M, Lu XM, Christian DA, Perazzelli J, Lacey SF, Roy NH, Burkhardt JK, Colomb F, Damra M, Abdel-Mohsen M, Liu T, Liu D, Standley DM, Young RM, Brogdon JL, Grupp SA, June CH, Maude SL, Gill S, Ruella M. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat Med 2021;27:842-50. [PMID: 33888899 DOI: 10.1038/s41591-021-01326-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Salvaris R, Ong J, Gregory GP. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J Pers Med 2021;11:355. [PMID: 33946635 DOI: 10.3390/jpm11050355] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Zhao H, Wang Y, Yin ETS, Zhao K, Hu Y, Huang H. A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma. Front Med 2020;14:711-25. [DOI: 10.1007/s11684-020-0808-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
100 DiNofia AM, Maude SL. Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL. Hemasphere 2019;3:e279. [PMID: 31723849 DOI: 10.1097/HS9.0000000000000279] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
101 Gupta KK, Khan MA, Singh SK. Constitutive Inflammatory Cytokine Storm: A Major Threat to Human Health. J Interferon Cytokine Res 2020;40:19-23. [PMID: 31755797 DOI: 10.1089/jir.2019.0085] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
102 Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, Horowitz MM, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv 2020;4:5414-24. [PMID: 33147337 DOI: 10.1182/bloodadvances.2020003092] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 42.0] [Reference Citation Analysis]
103 Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol 2020;13:125. [PMID: 32943087 DOI: 10.1186/s13045-020-00962-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
104 Balke-Want H, Borchmann P. [CAR T-cell therapy for malignant B-cell lymphoma : A new treatment paradigm]. Internist (Berl) 2021;62:589-96. [PMID: 34152469 DOI: 10.1007/s00108-021-01056-3] [Reference Citation Analysis]
105 Jiang H, Hu Y, Mei H. Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why? Biomark Res 2020;8:66. [PMID: 33292685 DOI: 10.1186/s40364-020-00247-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
106 Wang K, Zhao Y, Wang X, Wang B, Qin M, Zhu G, Wu H, Liu Z, Zheng X, Zheng H, Chen Z. Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy. Front Immunol 2020;11:581116. [PMID: 33424835 DOI: 10.3389/fimmu.2020.581116] [Reference Citation Analysis]
107 Moradian N, Gouravani M, Salehi MA, Heidari A, Shafeghat M, Hamblin MR, Rezaei N. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality. Eur Cytokine Netw 2020;31:81-93. [PMID: 33361013 DOI: 10.1684/ecn.2020.0451] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
108 La HT, Tran DBT, Tran HM, Nguyen LT. Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis. J Immunol Res 2021;2021:5575260. [PMID: 34189144 DOI: 10.1155/2021/5575260] [Reference Citation Analysis]
109 Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, Getz KD, Brogdon JL, Fesnak AD, Siegel DL, Davis MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, Grupp SA, Maude SL. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. J Clin Oncol 2021;:JCO2003458. [PMID: 34156874 DOI: 10.1200/JCO.20.03458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
110 Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat Rev Clin Oncol 2021. [PMID: 34230645 DOI: 10.1038/s41571-021-00530-z] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
111 Gauthier J. Traitement par cellules CAR-T : état des lieux de leur utilisation aux États-Unis en 2018. Bull Cancer 2018;105 Suppl 2:S214-7. [PMID: 30686360 DOI: 10.1016/S0007-4551(19)30052-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
112 Vairy S, Garcia JL, Teira P, Bittencourt H. CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Drug Des Devel Ther 2018;12:3885-98. [PMID: 30518999 DOI: 10.2147/DDDT.S138765] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 11.3] [Reference Citation Analysis]
113 Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma. BMJ 2020;370:m3176. [PMID: 32958461 DOI: 10.1136/bmj.m3176] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 11.0] [Reference Citation Analysis]
114 Vitale C, Strati P. CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. Front Oncol 2020;10:849. [PMID: 32670869 DOI: 10.3389/fonc.2020.00849] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 22.0] [Reference Citation Analysis]
115 Long B, Brém E, Koyfman A. Oncologic Emergencies: Immune-Based Cancer Therapies and Complications. West J Emerg Med 2020;21:566-80. [PMID: 32421502 DOI: 10.5811/westjem.2020.1.45898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
116 Wesley SF, Haggiagi A, Thakur KT, De Jager PL. Neurological Immunotoxicity from Cancer Treatment. Int J Mol Sci 2021;22:6716. [PMID: 34201529 DOI: 10.3390/ijms22136716] [Reference Citation Analysis]
117 Li C, Zhang Y, Zhang C, Chen J, Lou X, Chen X, Kang L, Xu N, Li M, Tan J, Sun X, Zhou J, Yang Z, Zong X, Wang P, Xu T, Qu C, Huang H, Jin Z, Yu L, Wu D. Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma. JCI Insight 2019;5:130195. [PMID: 31335321 DOI: 10.1172/jci.insight.130195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
118 Jain T, Litzow MR. No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Hematology Am Soc Hematol Educ Program 2018;2018:25-34. [PMID: 30504288 DOI: 10.1182/asheducation-2018.1.25] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
119 Liu D, Zhao J. Frontline therapies for untreated chronic lymphoid leukemia. Exp Hematol Oncol 2019;8:15. [PMID: 31428514 DOI: 10.1186/s40164-019-0139-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
120 Ho JY, Wang L, Liu Y, Ba M, Yang J, Zhang X, Chen D, Lu P, Li J. Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo. Mol Ther Methods Clin Dev 2021;21:237-46. [PMID: 33869653 DOI: 10.1016/j.omtm.2021.03.007] [Reference Citation Analysis]
121 Baik AH, Oluwole OO, Johnson DB, Shah N, Salem JE, Tsai KK, Moslehi JJ. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circ Res 2021;128:1780-801. [PMID: 33934609 DOI: 10.1161/CIRCRESAHA.120.315894] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 2020;8:e001511. [PMID: 33335028 DOI: 10.1136/jitc-2020-001511] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 29.0] [Reference Citation Analysis]
123 Jia H, Wang Z, Wang Y, Liu Y, Dai H, Tong C, Guo Y, Guo B, Ti D, Han X, Yang Q, Wu Z, Han W. Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation. J Hematol Oncol 2019;12:57. [PMID: 31182121 DOI: 10.1186/s13045-019-0741-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 15.0] [Reference Citation Analysis]
124 Lim FLWI, Ang SO. Emerging CAR landscape for cancer immunotherapy. Biochem Pharmacol 2020;178:114051. [PMID: 32446888 DOI: 10.1016/j.bcp.2020.114051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
125 Brown ART, Gutierrez C. Comments Regarding "ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells". Biol Blood Marrow Transplant 2019;25:e209-10. [PMID: 30862467 DOI: 10.1016/j.bbmt.2019.02.027] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 Myers RM, Dolan J, Teachey DT. Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia. Expert Rev Clin Immunol 2020;16:1029-42. [PMID: 32975147 DOI: 10.1080/1744666X.2021.1828067] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
127 Sievers S, Watson G, Johncy S, Adkins S. Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective. Front Oncol 2020;10:885. [PMID: 32670871 DOI: 10.3389/fonc.2020.00885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
128 Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, Yang Q, Nie J, Tang N, Zhang X, Cheng C, Shen L, He J, Ye X, Cao W, Wang H, Han W. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol 2021. [PMID: 34381179 DOI: 10.1038/s41423-021-00749-x] [Reference Citation Analysis]
129 Furzer J, Gupta S, Nathan PC, Schechter T, Pole JD, Krueger J, Pechlivanoglou P. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada. JAMA Oncol 2020;6:393-401. [PMID: 31971547 DOI: 10.1001/jamaoncol.2019.5909] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
130 Meng J, Wu X, Sun Z, Xun R, Liu M, Hu R, Huang J. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:698607. [PMID: 34381720 DOI: 10.3389/fonc.2021.698607] [Reference Citation Analysis]
131 Frey N, Porter D. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biol Blood Marrow Transplant 2019;25:e123-7. [PMID: 30586620 DOI: 10.1016/j.bbmt.2018.12.756] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 25.0] [Reference Citation Analysis]
132 Montoro J, Piñana JL, Sanz J, Guerreiro M. T lymphocytes as therapeutic arsenal for patients with hematological malignancies. Current Opinion in Oncology 2018;30:425-34. [DOI: 10.1097/cco.0000000000000481] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
133 Jeremias I, Schewe DM. Characteristics and Therapeutic Targeting of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia. Adv Exp Med Biol 2018;1100:127-39. [PMID: 30411264 DOI: 10.1007/978-3-319-97746-1_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Hirayama AV, Turtle CJ. Toxicities of CD19 CAR-T cell immunotherapy. Am J Hematol 2019;94:S42-9. [PMID: 30784102 DOI: 10.1002/ajh.25445] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 20.5] [Reference Citation Analysis]
135 Hopfinger G, Jäger U, Worel N. CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope. Hemasphere 2019;3:e185. [PMID: 31723824 DOI: 10.1097/HS9.0000000000000185] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
136 Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 2021;18:71-84. [PMID: 32978608 DOI: 10.1038/s41571-020-0427-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 26.0] [Reference Citation Analysis]
137 Yoon JG, Smith D, Tirumani SH, Caimi PF, Ramaiya N. CAR T-Cell Therapy: An Update for Radiologists. AJR Am J Roentgenol 2021. [PMID: 34191544 DOI: 10.2214/AJR.21.26091] [Reference Citation Analysis]
138 Viardot A, Locatelli F, Stieglmaier J, Zaman F, Jabbour E. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Ann Hematol 2020;99:2215-29. [PMID: 32856140 DOI: 10.1007/s00277-020-04221-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
139 Alnefaie A, Albogami S. Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective. Saudi Pharm J 2020;28:1333-52. [PMID: 32905015 DOI: 10.1016/j.jsps.2020.08.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
140 Zhao J, Song Y, Liu D. Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. J Hematol Oncol 2019;12:17. [PMID: 30764841 DOI: 10.1186/s13045-019-0705-x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 22.5] [Reference Citation Analysis]
141 Si Lim SJ, Grupp SA, DiNofia AM. Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2021;68:e29123. [PMID: 34061452 DOI: 10.1002/pbc.29123] [Reference Citation Analysis]
142 Thibodeaux SR, Milone MC. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory. Clin Chem 2019;65:519-29. [PMID: 30593467 DOI: 10.1373/clinchem.2016.258988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
143 Leahy AB, Elgarten CW, Grupp SA, Maude SL, Teachey DT. Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia. Expert Rev Anticancer Ther 2018;18:959-71. [PMID: 30111196 DOI: 10.1080/14737140.2018.1512411] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
144 Rooney C, Sauer T. Modeling cytokine release syndrome. Nat Med 2018;24:705-6. [PMID: 29808004 DOI: 10.1038/s41591-018-0068-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
145 Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Lancet Haematol 2020;7:e816-26. [PMID: 33091355 DOI: 10.1016/S2352-3026(20)30277-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 16.0] [Reference Citation Analysis]
146 Atrash S, Bano K, Harrison B, Abdallah AO. CAR-T treatment for hematological malignancies. J Investig Med 2020;68:956-64. [PMID: 32200355 DOI: 10.1136/jim-2020-001290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
147 Si S, Teachey DT. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. Ther Clin Risk Manag 2020;16:705-14. [PMID: 32801727 DOI: 10.2147/TCRM.S223468] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
148 Xie X, Hu Y, Ye T, Chen Y, Zhou L, Li F, Xi X, Wang S, He Y, Gao X, Wei W, Ma G, Li Y. Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen. Nat Biomed Eng 2021;5:414-28. [PMID: 33046865 DOI: 10.1038/s41551-020-00624-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
149 Kadauke S, Myers RM, Li Y, Aplenc R, Baniewicz D, Barrett DM, Barz Leahy A, Callahan C, Dolan JG, Fitzgerald JC, Gladney W, Lacey SF, Liu H, Maude SL, McGuire R, Motley LS, Teachey DT, Wertheim GB, Wray L, DiNofia AM, Grupp SA. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol 2021;39:920-30. [PMID: 33417474 DOI: 10.1200/JCO.20.02477] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 16.0] [Reference Citation Analysis]
150 Komanduri KV. Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma. JCO 2021;39:476-86. [DOI: 10.1200/jco.20.01749] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
151 Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25:625-638. [PMID: 30592986 DOI: 10.1016/j.bbmt.2018.12.758] [Cited by in Crossref: 600] [Cited by in F6Publishing: 475] [Article Influence: 200.0] [Reference Citation Analysis]
152 Sánchez-Escamilla M, Yáñez San Segundo L, Urbano-Ispizua Á, Perales MÁ. CAR T cells: The future is already present. Med Clin (Barc) 2019;152:281-6. [PMID: 30392694 DOI: 10.1016/j.medcli.2018.08.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
153 Chen Y, Li R, Shang S, Yang X, Li L, Wang W, Wang Y. Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation. Front Immunol 2021;12:623610. [PMID: 34093519 DOI: 10.3389/fimmu.2021.623610] [Reference Citation Analysis]
154 Zhao J, Song Y, Liu D. Recent advances on blinatumomab for acute lymphoblastic leukemia. Exp Hematol Oncol 2019;8:28. [PMID: 31709129 DOI: 10.1186/s40164-019-0152-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]